Contact

What we are looking for

SMEs, academia, and research institutions. (Large Pharma companies are permitted to apply but must be ready to cover their own...

shape
  1. SMEs, academia, and research institutions. (Large Pharma companies are permitted to apply but must be ready to cover their own costs).
  2. Research into high-burden drug-resistant bacterial infections across LRTIs, UTIs, BSIs, IAIs, including pneumonia, sepsis, and bacteraemia.
  3. Bacterial infections associated with WHO critical priority Gram-negative pathogens Enterobacteriaceae (prioritising coli and K. pneumoniae), A. baumannii, P. aeruginosa, and high-priority Gram-positive infections (specifically S. aureus oral route).
  4. Hit validation, Hit-to-lead, or Lead optimisation stage.
  5. A clear focus on novel, targeted therapeutics only, but can be modality agnostic.
  6. Can include direct, indirect-acting, potentiators and anti-virulence approaches.
Posted 03 / 08 / 23